273 related articles for article (PubMed ID: 33457090)
1. Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses.
Shevchenko I; Mathes A; Groth C; Karakhanova S; Müller V; Utikal J; Werner J; Bazhin AV; Umansky V
Oncoimmunology; 2020 Apr; 9(1):1744946. PubMed ID: 33457090
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
[TBL] [Abstract][Full Text] [Related]
3. Extracellular adenosine metabolism in immune cells in melanoma.
Umansky V; Shevchenko I; Bazhin AV; Utikal J
Cancer Immunol Immunother; 2014 Oct; 63(10):1073-80. PubMed ID: 24756420
[TBL] [Abstract][Full Text] [Related]
4. CD73-mediated adenosine production promotes stem cell-like properties in mouse Tc17 cells.
Flores-Santibáñez F; Fernández D; Meza D; Tejón G; Vargas L; Varela-Nallar L; Arredondo S; Guixé V; Rosemblatt M; Bono MR; Sauma D
Immunology; 2015 Dec; 146(4):582-94. PubMed ID: 26331349
[TBL] [Abstract][Full Text] [Related]
5. CD73 Inhibits cGAS-STING and Cooperates with CD39 to Promote Pancreatic Cancer.
Jacoberger-Foissac C; Cousineau I; Bareche Y; Allard D; Chrobak P; Allard B; Pommey S; Messaoudi N; McNicoll Y; Soucy G; Koseoglu S; Masia R; Lake AC; Seo H; Eeles CB; Rohatgi N; Robson SC; Turcotte S; Haibe-Kains B; Stagg J
Cancer Immunol Res; 2023 Jan; 11(1):56-71. PubMed ID: 36409930
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate up-regulates ecto-5'-nucleotidase/CD73 and reduces the frequency of T lymphocytes in the glioblastoma microenvironment.
Figueiró F; de Oliveira CP; Bergamin LS; Rockenbach L; Mendes FB; Jandrey EH; Moritz CE; Pettenuzzo LF; Sévigny J; Guterres SS; Pohlmann AR; Battastini AM
Purinergic Signal; 2016 Jun; 12(2):303-12. PubMed ID: 26910734
[TBL] [Abstract][Full Text] [Related]
7. Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways.
Giatromanolaki A; Kouroupi M; Pouliliou S; Mitrakas A; Hasan F; Pappa A; Koukourakis MI
Life Sci; 2020 Oct; 259():118389. PubMed ID: 32898522
[TBL] [Abstract][Full Text] [Related]
8. Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape.
Montalbán Del Barrio I; Penski C; Schlahsa L; Stein RG; Diessner J; Wöckel A; Dietl J; Lutz MB; Mittelbronn M; Wischhusen J; Häusler SFM
J Immunother Cancer; 2016; 4():49. PubMed ID: 27532024
[TBL] [Abstract][Full Text] [Related]
9. Low Pretreatment CD4
Turner RJ; Guy TV; Geraghty NJ; Splitt A; Watson D; Brungs D; Carolan MG; Miller AA; de Leon JF; Aghmesheh M; Sluyter R
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628721
[TBL] [Abstract][Full Text] [Related]
10. The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment.
De Marchi E; Orioli E; Pegoraro A; Sangaletti S; Portararo P; Curti A; Colombo MP; Di Virgilio F; Adinolfi E
Oncogene; 2019 May; 38(19):3636-3650. PubMed ID: 30655604
[TBL] [Abstract][Full Text] [Related]
11. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.
Häusler SF; Montalbán del Barrio I; Strohschein J; Chandran PA; Engel JB; Hönig A; Ossadnik M; Horn E; Fischer B; Krockenberger M; Heuer S; Seida AA; Junker M; Kneitz H; Kloor D; Klotz KN; Dietl J; Wischhusen J
Cancer Immunol Immunother; 2011 Oct; 60(10):1405-18. PubMed ID: 21638125
[TBL] [Abstract][Full Text] [Related]
12. CD39 is upregulated during activation of mouse and human T cells and attenuates the immune response to Listeria monocytogenes.
Raczkowski F; Rissiek A; Ricklefs I; Heiss K; Schumacher V; Wundenberg K; Haag F; Koch-Nolte F; Tolosa E; Mittrücker HW
PLoS One; 2018; 13(5):e0197151. PubMed ID: 29742141
[TBL] [Abstract][Full Text] [Related]
13. Autocrine Adenosine Regulates Tumor Polyfunctional CD73
Gourdin N; Bossennec M; Rodriguez C; Vigano S; Machon C; Jandus C; Bauché D; Faget J; Durand I; Chopin N; Tredan O; Marie JC; Dubois B; Guitton J; Romero P; Caux C; Ménétrier-Caux C
Cancer Res; 2018 Jul; 78(13):3604-3618. PubMed ID: 29559470
[TBL] [Abstract][Full Text] [Related]
14. CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer.
Li J; Wang L; Chen X; Li L; Li Y; Ping Y; Huang L; Yue D; Zhang Z; Wang F; Li F; Yang L; Huang J; Yang S; Li H; Zhao X; Dong W; Yan Y; Zhao S; Huang B; Zhang B; Zhang Y
Oncoimmunology; 2017; 6(6):e1320011. PubMed ID: 28680754
[TBL] [Abstract][Full Text] [Related]
15. CD73 Ectonucleotidase Restrains CD8+ T Cell Metabolic Fitness and Anti-tumoral Activity.
Briceño P; Rivas-Yañez E; Rosemblatt MV; Parra-Tello B; Farías P; Vargas L; Simon V; Cárdenas C; Lladser A; Salazar-Onfray F; Elorza AA; Rosemblatt M; Bono MR; Sauma D
Front Cell Dev Biol; 2021; 9():638037. PubMed ID: 33681221
[TBL] [Abstract][Full Text] [Related]
16. Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73
Ahmadi P; Hartjen P; Kohsar M; Kummer S; Schmiedel S; Bockmann JH; Fathi A; Huber S; Haag F; Schulze Zur Wiesch J
Cells; 2020 Jul; 9(8):. PubMed ID: 32707842
[TBL] [Abstract][Full Text] [Related]
17. Decreased frequency of CD73+CD8+ T cells of HIV-infected patients correlates with immune activation and T cell exhaustion.
Tóth I; Le AQ; Hartjen P; Thomssen A; Matzat V; Lehmann C; Scheurich C; Beisel C; Busch P; Degen O; Lohse AW; Eiermann T; Fätkenheuer G; Meyer-Olson D; Bockhorn M; Hauber J; van Lunzen J; Schulze Zur Wiesch J
J Leukoc Biol; 2013 Oct; 94(4):551-61. PubMed ID: 23709688
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.
Bastid J; Regairaz A; Bonnefoy N; Déjou C; Giustiniani J; Laheurte C; Cochaud S; Laprevotte E; Funck-Brentano E; Hemon P; Gros L; Bec N; Larroque C; Alberici G; Bensussan A; Eliaou JF
Cancer Immunol Res; 2015 Mar; 3(3):254-65. PubMed ID: 25403716
[TBL] [Abstract][Full Text] [Related]
19. Increased frequency of TIGIT
Brauneck F; Haag F; Woost R; Wildner N; Tolosa E; Rissiek A; Vohwinkel G; Wellbrock J; Bokemeyer C; Schulze Zur Wiesch J; Ackermann C; Fiedler W
Oncoimmunology; 2021 Jun; 10(1):1930391. PubMed ID: 34211801
[TBL] [Abstract][Full Text] [Related]
20. CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models.
Ye J; Gavras NW; Keeley DC; Hughson AL; Hannon G; Vrooman TG; Lesch ML; Johnston CJ; Lord EM; Belt BA; Linehan DC; Eyles J; Gerber SA
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37142292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
